USPTO session features debates about PTAB value for life sciences patents
Advocates for the pharmaceutical industry argued at a US Patent and Trademark Office event Monday that inter partes review challenges at the Patent Trial and Appeal Board are duplicative and unnecessary,...To view the full article, register now.
Already a subscriber? Click here to view full article